Mad honey is marketed and traditionally used for a range of health purposes: lowering blood pressure, improving blood sugar control, enhancing sexual performance, relieving gastrointestinal complaints, and treating pain. These claims are widespread across commercial sellers and folk medicine traditions in Nepal and Turkey. The evidence supporting them is far narrower and more qualified than the marketing suggests.
This article separates the three categories that usually get blended together: what mad honey is traditionally and commercially claimed to do, what the published research has actually measured, and what level of evidence sits behind each finding. The short version: most therapeutic claims rest on animal studies, traditional use, or extrapolation from the honey-general literature. No human clinical trial has evaluated any therapeutic application of mad honey or grayanotoxin.
There is also a structural point that makes mad honey different from ordinary functional foods. The compound responsible for the effects people seek, grayanotoxin, is the same compound responsible for the cardiovascular toxicity that sends people to the emergency department. The claimed benefit and the documented harm are not separate properties. They are two expressions of one sodium channel mechanism. Any honest account of the benefits has to hold the risk in the same frame.
What Mad Honey Is Claimed to Do
The claims fall into five broad categories, drawn from folk medicine accounts and commercial product descriptions.
- Cardiovascular: lowering high blood pressure. This is the most common traditional use in Turkey and the one with the most underlying mechanism plausibility, for reasons explained below.
- Metabolic: lowering blood sugar and supporting diabetes management.
- Sexual health: enhancing libido and treating erectile dysfunction. This is the dominant marketing angle in the Western import market.
- Gastrointestinal: relieving gastritis, ulcers, and indigestion.
- General: anti-inflammatory effects, pain relief, wound healing, and immune support, often grouped together as a tonic or restorative.
What the Evidence Actually Shows, and at What Level
The table below maps each claimed benefit to the strongest evidence that exists for it and the level of that evidence. The pattern is consistent: where research exists, it is almost entirely from animal models, not human trials.
| Claimed benefit | Strongest evidence | Evidence level | What it does not establish |
| Blood pressure reduction | Animal studies show GTX lowers blood pressure (e.g. Turkmen et al. 2013) | Animal only | No controlled human trial. The effect is the toxic mechanism, not a controlled therapy. |
| Blood glucose-lowering | Animal studies report reduced blood glucose (e.g. Oztasan et al. 2005) | Animal only | No human trial. No dose-response or safety data in diabetic patients. |
| Fracture/bone healing | Animal study reports enhanced fracture healing (Sahin et al. 2018) | Animal only | No human evidence of any kind. |
| Anti-epileptiform activity | The animal model shows an anti-epileptiform effect (Gunduz et al. 2012) | Animal only | No human trial. Mechanistically complex given GTX neuroactivity. |
| Sexual performance/libido | Traditional use; no controlled study of GTX honey for this purpose | Anecdotal | No clinical evidence. The vasodilatory effect is part of the toxic profile, not a validated treatment. |
| Gastritis/ulcers / GI | Traditional use: honey-general antimicrobial literature | Indirect/general honey | No GTX-specific human study. Any effect may be a honey property, not a GTX property. |
| Antioxidant / antimicrobial | Honey-general literature; some mad honey samples assayed in vitro | In vitro / general honey | Not specific to GTX and not demonstrated to produce a clinical benefit in humans. |
Blood pressure: the clearest example of why benefit and risk are the same thing
Of all the claimed benefits, blood pressure reduction has the most mechanistic plausibility, and it illustrates the central problem most clearly. Grayanotoxin lowers blood pressure in animal models. It does so by the same actions that define grayanotoxin poisoning: it slows the heart through vagal stimulation and it relaxes vascular smooth muscle, reducing peripheral resistance. The hypotension that a traditional user is seeking and the hypotension that a poisoning patient presents with are the same physiological event at different magnitudes.
This is why a clean separation of benefit from harm is not possible for mad honey. A dose large enough to meaningfully lower blood pressure is operating through the toxic mechanism. There is no established therapeutic window in humans that delivers a controlled antihypertensive effect without cardiovascular risk, because no human study has ever defined one.
The therapeutic research is real, and it is entirely preclinical
The animal evidence is nothing. The 2025 review by Aryal from Tribhuvan University in Nepal synthesises the preclinical findings: blood pressure reduction, blood glucose lowering, fracture healing enhancement, and anti-epileptiform activity, each from animal studies. These are legitimate research signals that justify further investigation. They are not evidence of a benefit in humans, and they are routinely misrepresented as if they were.
The distance between an animal finding and a human therapy is large. It includes human pharmacokinetics, dose-response, safety in vulnerable populations, drug interactions, and controlled trials, none of which exist for mad honey. Presenting an animal blood-pressure finding as a reason to consume mad honey for hypertension skips every one of those steps.
The Critical Caveat: No Human Clinical Trial Exists
| This is the single most important fact about mad honey benefits No randomised controlled trial, and no controlled human study of any design, has evaluated mad honey or grayanotoxin for any therapeutic purpose. Every therapeutic claim, therefore, rests on one of three weaker foundations: animal studies, traditional use, or extrapolation from the general honey literature. This is not a temporary gap that some sources have overlooked. It is the defining feature of the evidence base. Anyone presenting mad honey as a proven treatment for a medical condition is overstating what is known. |
Traditional Use Is Documented, but Documentation Is Not Validation
Mad honey has a long and genuine history of traditional use. In Nepal, Gurung communities have used cliff honey both as food and for folk medicinal purposes. In Turkey, deli bal has been used traditionally for hypertension, gastrointestinal complaints, and sexual performance. This history is real and culturally significant.
Traditional use tells us that people have used a substance and value it. It does not tell us that the substance is effective, that it is safe, or that the effect attributed to it is the effect it actually produces. Many traditional remedies have been validated by later research, many have been found inert, and many have been found actively harmful. Traditional use is a reason to investigate, not a substitute for the investigation. For mad honey, the investigation in humans has not been done.
The Honest Reading
If someone asks whether mad honey has benefits, the accurate answer has several parts. There are documented effects in animal models, particularly on blood pressure and blood glucose, that are scientifically interesting. There is a long tradition of human use. And there is no human clinical evidence that these translate into a safe, effective treatment for any condition.
There is also a specific reason for caution that ordinary functional foods do not carry. The mechanism behind the effects people seek is the same mechanism that causes grayanotoxin poisoning. The cardiovascular effect is dose-dependent and the concentration of active compound in any given batch of honey is highly variable, by as much as 86-fold across real-world samples in one Nepal study. A person attempting to use mad honey for a claimed benefit has no reliable way to know how much active compound they are consuming, and the effect they are seeking shades into the toxic effect without a clear boundary.
What We Don’t Know Yet
Whether any claimed benefit holds in humans. No controlled human trial has tested any therapeutic application.
Whether a therapeutic window exists. Whether there is any dose that delivers a claimed benefit without cardiovascular risk in humans has never been studied or defined.
Whether the effects are GTX-specific or honey-general. Some claimed benefits, particularly antimicrobial and antioxidant effects, may be properties of honey in general rather than of grayanotoxin, and have not been separated in mad honey research.
Long-term effects. The animal genotoxicity findings (discussed in the research literature as animal evidence at chronic doses) mean that the long-term safety profile in humans is also uncharacterised.
Summary
Mad honey is claimed to lower blood pressure, improve blood sugar, enhance sexual performance, relieve gastrointestinal complaints, and provide general tonic effects. The strongest evidence for the metabolic and cardiovascular claims comes from animal studies. The sexual-performance and gastrointestinal claims rest on traditional use and general honey literature rather than direct evidence. No human clinical trial has evaluated any therapeutic application of mad honey or grayanotoxin.
The defining feature of mad honey, which separates it from ordinary functional foods, is that the mechanism behind its claimed benefits is the same sodium channel mechanism behind grayanotoxin poisoning. The blood-pressure-lowering effect a traditional user seeks, and the hypotension a poisoning patient presents with, are the same event. Benefit and risk cannot be separated, and no human study has ever defined a safe therapeutic dose. The accurate position is that the animal evidence is interesting, the traditional use is real, and the human therapeutic case is unproven.
